List of nationally authorised medicinal products
|
|
- Gregory Booth
- 5 years ago
- Views:
Transcription
1 12 April 2018 EMA/382206/2018 Human Medicines Evaluation Division Active substance(s): naproxen Procedure No.: PSUSA/ / Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone +44 (0) Facsimile +44 (0) Send a question via our website An agency of the European Union European Medicines Agency, Reproduction provided the source is acknowledged.
2 MOMENDOL 220 mg plėvele dengtos tabletės not available LT/1/04/0014/001 AZIENDE CHIMICHE RIUNE AZIENDE CHIMICHE RIUNE MOMENDOL 220 mg plėvele dengtos tabletės not available LT/1/04/0014/002 LT Eox 220 mg filmdragerade tabletter /H/0110/ MEDA OTC AB FI AZIENDE CHIMICHE RIUNE Momendol, filmomhulde tabletten 220 mg /H/0110/001 RVG NL Momendol 220 mg - Filmtabletten /H/0110/ MOMENDOL 220 mg comprimés pelliculés /H/0110/ /02/ Momendol 220 mg film-coated tablets /H/0110/001 PA 959/2/1 Momendol 220 mg Filmtabletten /H/0110/ MOMENDOL 220 mg compresse rivestite con film /H/0110/ AZIENDE CHIMICHE RIUNE AZIENDE CHIMICHE RIUNE AZIENDE CHIMICHE RIUNE AZIENDE CHIMICHE RIUNE AZIENDE CHIMICHE RIUNE AZIENDE CHIMICHE RIUNE MOMENDOL 220 mg compresse rivestite con film /H/0110/ Momendol comprimidos revestidos por película /H/0110/ ANGELINI FARMACÊUTICA, LDA PT Momendol comprimidos revestidos por película /H/0110/ ANGELINI FARMACÊUTICA, LDA PT Momendol 220 mg επικαλυμμένα με λεπτό υμένιο δισκία /H/0110/ / ANGELINI PHARMA HELLAS S.A. GR Eox 220 mg filmdragerade tabletter /H/0110/ MEDA OTC AB SE Eox 220 mg kalvopäällysteinen tabletti /H/0110/ MEDA OTC AB FI Eox /H/0110/ MEDA OTC AB DK LT AT LU IE DE EMA/382206/2018 Page 2/9
3 Naproxen Saft InfectoPharm 250 mg/5 ml Suspension zum Einnehmen not available INFECTOPHARM ARZNEIMTEL UND CONSILIUM GMBH AT Proxen 500 mg - Filmtabletten not available GRÜNENTHAL GES. M.B.H. AT NAPSYN not available 29/0729/92-S SK NAPREBEN 550 mg capsule rigide not available MERQURIO PHARMA S.R.L. NAPREBEN 10% gel not available MERQURIO PHARMA S.R.L. MOMENDOL 10% w/w GEL /H/0110/002 PA0959/002/002 AZIENDE CHIMICHE RIUNE IE MOMENDOL 10% gel /H/0110/ AZIENDE CHIMICHE RIUNE MOMENDOL 10% gel /H/0110/ AZIENDE CHIMICHE RIUNE Momendol 100 mg/g (10%) gel /H/0110/ ANGELINI FARMACÊUTICA, LDA PT Momendol 100 mg/g (10%) gel /H/0110/ ANGELINI FARMACÊUTICA, LDA PT MOMENDOL 10% w/w GEL /H/0110/ / ANGELINI PHARMA HELLAS S.A. GR Synflex 550 mg compresse rivestite not available FARMACEUTICA Naprosyn 10% gel not available FARMACEUTICA Naprosyn 250 mg compresse gastroresistenti not available FARMACEUTICA Naprosyn 500 mg compresse gastroresistenti not available FARMACEUTICA Naprosyn 500 mg supposte not available FARMACEUTICA Naprosyn 250 mg granulato per sospensione orale not available FARMACEUTICA Naprosyn 500 mg granulato per sospensione orale not available FARMACEUTICA Naprosyn 750 mg compresse a rilascio modificato not available FARMACEUTICA Synflex 275 mg capsule rigide not available EMA/382206/2018 Page 3/9
4 FARMACEUTICA Synflex 550 mg compresse rivestite not available FARMACEUTICA Synflex 550 mg granulato per sospensione orale not available FARMACEUTICA Naproxen 500mg Tablets not available PL 44041/0026 NOUMED LIFE SCIENCES UK Laser 750 mg compresse a rilascio controllato not available EURO-PHARMA S.R.L. Naproxen Sandoz 500 mg tabletten not available BE SANDOZ N.V. BE Naproxen Sandoz 250 mg tabletten not available BE SANDOZ N.V. BE Naprosyn 250 mg tabletta not available OGYI-T- 3556/01 Dolormin GS mit Naproxen 250 mg tabletten not available JOHNSON & JOHNSON GMBH DE Dolormin für Frauen bei Menstruationsbeschwerden mit Naproxen not available JOHNSON & JOHNSON GMBH DE Dolormin für Frauen bei Menstruationsbeschwerden mit Naproxen not available JOHNSON & JOHNSON GMBH DE Dolormin für Frauen bei Menstruationsbeschwerden mit Naproxen not available JOHNSON & JOHNSON GMBH DE Dolormin GS mit Naproxen 250 mg tabletten not available JOHNSON & JOHNSON GMBH DE Dolormin GS mit Naproxen 250 mg tabletten not available JOHNSON & JOHNSON GMBH DE PREXAN 500 mg compresse not available NEW RESEARCH SRL PREXAN 500 mg granulato per sospensione orale not available NEW RESEARCH SRL PREXAN 10% Crema not available NEW RESEARCH SRL Naproxen Apotex 250 mg, zetpillen not available RVG APOTEX EUROPE B.V. NL Naproxen Apotex 500 mg, zetpillen not available RVG APOTEX EUROPE B.V. NL ALEVE 220 mg, Filmtabletten not available BE BAYER SA NV BE 220 mg compresse rivestite con film not available BAYER SPA EMA/382206/2018 Page 4/9
5 220 mg compresse rivestite con film not available BAYER SPA Aleve filmtabletta not available OGYI-T-8021/03 BAYER NGARIA KFT Aleve filmtabletta not available OGYI-T-8021/04 BAYER NGARIA KFT Aleve filmtabletta not available OGYI-T-8021/05 BAYER NGARIA KFT Aleve filmtabletta not available OGYI-T-8021/01 BAYER NGARIA KFT ALEVE 220 mg, Filmtabletten not available BAYER SA NV LU 660 mg compresse a rilascio modificato not available BAYER SPA 660 mg compresse a rilascio modificato not available BAYER SPA 660 mg compresse a rilascio modificato not available BAYER SPA ALEVETABS 220 mg, comprimé pelliculé not available BAYER HEALTHCARE ALEVETABS 220 mg, comprimé pelliculé not available BAYER HEALTHCARE ALEVETABS 220 mg, comprimé pelliculé not available BAYER HEALTHCARE ALEVE 220 mg, comprimé pelliculé not available BAYER HEALTHCARE ALEVE 220 mg, comprimé pelliculé not available BAYER HEALTHCARE ALEVE 220 mg, comprimé pelliculé not available BAYER HEALTHCARE ALEVE 220 mg, comprimé pelliculé not available BAYER HEALTHCARE Aleve Extra 660 mg retard tabletta not available OGYI-T-8021/06 BAYER NGARIA KFT Aleve Extra 660 mg retard tabletta not available OGYI-T-8021/08 BAYER NGARIA KFT Aleve Extra 660 mg retard tabletta not available OGYI-T-8021/07 BAYER NGARIA KFT Feminax Ultra 250mg Gastro-Resistant Tablets not available PL 00010/0631 BAYER PLC UK Aleve filmtabletta not available OGYI-T-8021/02 BAYER NGARIA KFT Aleve Feminax bij menstruatiepijn 275 not available RVG BAYER BV NL ALEVE not available BAYER HISPANIA SL ES Aleve Select 275 mg, omhulde tabletten not available RVG BAYER BV NL ALEVE - Filmtabletten not available BAYER AUSTRIA GMBH AT 220 mg compresse rivestite con film not available BAYER SPA 220 mg compresse rivestite con film not available BAYER SPA ALEVE 220 mg comprimés pelliculés not available BAYER SA NV LU EMA/382206/2018 Page 5/9
6 ALEVE 220 mg filmomhulde tabletten not available BE BAYER SA NV BE ALEVE 220 mg comprimés pelliculés not available BE BAYER SA NV BE Aktren Naproxen Filmtablette mit 220 mg Naproxen-Natrium not available BAYER VAL GMBH DE Aleve Filmtablette mit 220 mg Naproxen-Natrium not available BAYER VAL GMBH DE Aleve Wirkstoff: Naproxen-Natrium not available BAYER VAL GMBH DE Aleve, 220 mg, tabletki powlekane not available 7756 BAYER SP.Z.O.O PL Aleve Intense 550 mg, omhulde tablet not available RVG BAYER BV NL ALEVETABS 220 mg, comprimé pelliculé not available BAYER HEALTHCARE ALEVE 220 mg, comprimé pelliculé not available BAYER HEALTHCARE Aleve Classic bij pijn en koorts 220, omhulde tabletten not available RVG BAYER BV NL NAPROSYN 10 %, γέλη not available 65484/13/ MINERVA PHARMACEUTICAL S.A GR NAPROSYN 250 mg, γαστροανθεκτικό δισκίο not available 23554/ MINERVA PHARMACEUTICAL S.A GR NAPROSYN 500 mg, γαστροανθεκτικό δισκίο not available 21622/ MINERVA PHARMACEUTICAL S.A GR NAPROSYN 250 mg, δισκία not available 60295/13/ MINERVA PHARMACEUTICAL S.A GR NAPROSYN 500 mg, δισκία not available 45244/ MINERVA PHARMACEUTICAL S.A GR ANAPROX 550mg δισκία επικαλυμμένα not available 85120/ MINERVA PHARMACEUTICAL S.A GR NAPROSYN 250 mg, υπόθετα not available 79750/09/ MINERVA PHARMACEUTICAL S.A GR NAPROSYN 500 mg, υπόθετα not available 21344/ MINERVA PHARMACEUTICAL S.A GR Miranax 550 mg - Filmtabletten not available GRÜNENTHAL GES. M.B.H. AT Момендол 220 mg филмирани таблетки not available Apranax 275 mg filmtabletta not available OGYI-T- 3742/01 Apranax 550 mg filmtabletta not available OGYI-T- 4030/01 Apranax 275 mg filmtabletta not available OGYI-T- 3742/01 AZIENDE CHIMICHE RIUNE Apranax 550 mg filmtabletta not available OGYI-T- 4030/01 NAPRIUS 10% GEL not available AESCULAPIUS FARMACEUTICI S.R.L. EMA/382206/2018 Page 6/9 BG
7 NAPRIUS 500 mg Compresse not available AESCULAPIUS FARMACEUTICI S.R.L. NAPRIUS 500 mg Granulato per sospensione orale not available AESCULAPIUS FARMACEUTICI S.R.L. Momendol 220 mg capsule molli not available AZIENDE CHIMICHE RIUNE Momendol 220 mg capsule molli not available AZIENDE CHIMICHE RIUNE Momendol 220 mg capsule molli not available AZIENDE CHIMICHE RIUNE Momendol 220 mg capsule molli not available AZIENDE CHIMICHE RIUNE Momendol 220 mg capsule molli not available AZIENDE CHIMICHE RIUNE NAPROSSENE ANGELINI 220 mg compresse rivestite con film not available NAPROSSENE ANGELINI 220 mg compresse rivestite con film not available MOMENDOL 220 mg granulato per soluzione orale not available AZIENDE CHIMICHE RIUNE AZIENDE CHIMICHE RIUNE AZIENDE CHIMICHE RIUNE AUROBINDO PHARMA (MALTA) LIMED Naproxen Orion 250 mg tabletit NL/H/3472/ FI Naproxeno Aurobindo 250 mg comprimidos NL/H/3472/ LABORATORIOS AUROBINDO S.L.U. ES Naproxen 250mg Gastro-resistant Tablets Period Pain Reliever 250mg Gastroresistant Tablets not available PL 20075/0619 ACCORD HEALTHCARE LIMED UK Galpharm Period Pain Relief 250mg Gastro-Resistant Tablets not available PL 16028/0144 GALPHARM HEALTHCARE LIMED UK EMA/382206/2018 Page 7/9
8 Naproxen Orion 25 mg/ml oral suspension FI/H/879/01/DC PL 27925/0087 ORION CORPORATION UK NAPROSYNE 250 mg, comprimé not available NAPROSYNE 250 mg, comprimé not available NAPROSYNE 500 mg, comprimé not available NAPROSYNE 500 mg, suppositoire not available NAPROSYNE 250 mg, comprimé not available NAPROSYNE 500 mg, suppositoire not available NAPROSYNE 250 mg, comprimé not available NAPROSYNE 500 mg, comprimé not available NAPROSYNE 500 mg, comprimé not available NAPROSYNE 500 mg, comprimé not available NAPROSYNE 250 mg, comprimé not available NAPROSYNE 1000 mg, comprimé not available NAPROSYNE 500 mg, suppositoire not available NAPROSYNE 250 mg, comprimé not available NAPROSYNE 250 mg, comprimé not available NAPROSYNE 500 mg, comprimé not available NAPROSYNE 500 mg, suppositoire not available EMA/382206/2018 Page 8/9
9 NAPROSYNE 250 mg, comprimé not available Naproxen Tablets BP 500mg not available PL 21880/0111 MEDREICH PLC UK Napren-E 250 mg enterotabletter not available 6998 TAKEDA AS NO Napren-E 375 mg enterotabletter not available TAKEDA AS NO Napren-E 500 mg enterotabletter not available 6999 TAKEDA AS NO Naprostad 250 mg Filmtabletten not available STADA ARZNEIMTEL AG DE Naprostad 500 mg Filmtabletten not available STADA ARZNEIMTEL AG DE EMA/382206/2018 Page 9/9
List of nationally authorised medicinal products
12 April 2018 EMA/231137/2018 Human Medicines Evaluation Division Active substance: fluvoxamine Procedure no.: PSUSA/00001458/201707 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationList of nationally authorised medicinal products
12 January 2017 EMA/36356/2017 Human Medicines Evaluation Division Active substance: hydroxyzine chloride / hydroxyzine pamoate and all fixed combination, hydroxyzine Procedure no.: PSUSA/00001696/201605
More informationList of nationally authorised medicinal products
27 October 2016 EMA/719205/2016 Human Medicines Evaluation Division Active substance: ethinylestradiol / gestodene (except for transdermal application) Procedure no.: PSUSA/00001308/201603 30 Churchill
More informationList of nationally authorised medicinal products
01 December 2016 Human Medicines Evaluation Division Active substance: Procedure no.: PSUSA/00002591/201604 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone +44 (0)20 3660 6000 Facsimile
More informationList of nationally authorised medicinal products
1 December 2016 EMA/750653/2016 Human Medicines Evaluation Division Active substance: valganciclovir Procedure no.: PSUSA/00003089/201603 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationList of nationally authorised medicinal products
06 July 2017 EMA/436040/2017 Human Medicines Evaluation Division Active substance: Procedure no.: PSUSA/00001815/201610 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone +44 (0)20
More informationList of nationally authorised medicinal products
29 September 2017 EMA/658556/2017 Procedure Management and Committees Support Active substance: loratadine Procedure no.: PSU/00001907/201702 30 Churchill Place Canary Wharf London E14 5EU United Kingdom
More informationList of nationally authorised medicinal products
12 April 2018 EMA/243033/2018 Human Medicines Evaluation Division Active substance: fenofibrate Procedure no.: PSUSA/00001362/201707 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationList of nationally authorised medicinal products
29 November 2018 EMA/880324/2018 Human Medicines Evaluation Division Active substance: enalapril Procedure no.: PSUSA/00001211/201803 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationList of nationally authorised medicinal products
6 September 2018 EMA/608492/2018 Human Medicines Evaluation Division Active substance: betahistine Procedure no.: PSUSA/00000389/201712 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationList of nationally authorised medicinal products
21 June 2017 EMA/610895/2017 Human Medicines Evaluation Division Active substance: felbamate Procedure no.: PSUSA/00010155/201609 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationList of nationally authorised medicinal products
17 May 2018 EMA/303456/2018 Human Medicines Evaluation Division Active substance: bromazepam Procedure no.: PSUSA/00000435/201708 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationList of nationally authorised medicinal products
11 January 2018 EMA/24585/2018 Human Medicines Evaluation Division Active substance: esomeprazole / naproxen Procedure no.: PSUSA/00001270/201704 30 Churchill Place Canary Wharf London E14 5EU United Kingdom
More informationList of nationally authorised medicinal products
08 March 2018 EMA/170163/2018 Human Medicines Evaluation Division Active substance: enalapril / hydrochlorothiazide Procedure no.: PSUSA/00001212/201707 30 Churchill Place Canary Wharf London E14 5EU United
More informationList of nationally authorised medicinal products
10 September 2015 EMA/612853/2015 Procedure Management and Committees Support Active substance: tobramycin (nebuliser solution) Procedure no.: PSUSA/00009316/201412 30 Churchill Place Canary Wharf London
More informationList of nationally authorised medicinal products
21 February 2018 EMA/208334/2018 Human Medicines Evaluation Division Active substance: ibuprofen / pseudoephedrine Procedure no.: PSUSA/00001711/201707 30 Churchill Place Canary Wharf London E14 5EU United
More informationList of nationally authorised medicinal products
10 September 2015 EMA/677092/2015 Procedure Management and Committees Support Active substance: glatiramer Procedure no.: PSUSA/00001529/201411 30 Churchill Place Canary Wharf London E14 5EU United Kingdom
More informationList of nationally authorised medicinal products
6 September 2018 EMA/615391/2018 Human Medicines Evaluation Division Active substance: tobramycin (nebuliser solution) (apart from centrally authorised product) Procedure no.: PSUSA/00009316/201712 30
More informationList of nationally authorised medicinal products
5 November 2015 EMA/230130/2016 Procedure Management and Committees Support Active substance: cabergoline Procedure no.: PSUSA/00000477/201503 30 Churchill Place Canary Wharf London E14 5EU United Kingdom
More informationList of nationally authorised medicinal products
30 November 2017 EMA/806830/2017 Human Medicines Evaluation Division Active substance: piroxicam Procedure no.: PSUSA/00002438/201704 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationList of nationally authorised medicinal products
12 April 2018 EMA/223740/2018 Human Medicines Evaluation Division Active substance: fludarabine Procedure no.: PSUSA/00001406/201708 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationList of nationally authorised medicinal products
30 November 2017 EMA/817337/2017 Human Medicines Evaluation Division Active substance: Itraconazole Procedure no.: PSUSA/00001798/201703 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationList of nationally authorised medicinal products
30 November 2017 EMA/812360/2017 Human Medicines Evaluation Division Active substance(s): mupirocin Procedure No.: PSUSA/00002096/201703 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationList of nationally authorised medicinal products
8 March 2018 EMA/182668/2018 Human Medicines Evaluation Division Active substance(s): triamcinolone (topical and nasal formulations) Procedure No.: PSUSA/00003017/201707 30 Churchill Place Canary Wharf
More informationList of nationally authorised medicinal products
26 October 2017 EMA/690754/2017 Human Medicines Evaluation Division Active substance: fish oil / olive oil / soybean oil / triglycerides mediumchain Procedure no.: PSUSA/00010223/201702 30 Churchill Place
More informationList of nationally authorised medicinal products
3 December 2015 EMA/98477/2016 Procedure Management and Committees Support Active substance: acarbose Procedure no.: PSUSA/00000017/201503 30 Churchill Place Canary Wharf London E14 5EU United Kingdom
More informationList of nationally authorised medicinal products
11 October 2017 EMA/784453/2017 Human Medicines Evaluation Division List of nationally authorised medicinal products Active substance(s): ipratropium / salbutamol Procedure No.: PSUSA/00001781/201701 30
More informationList of nationally authorised medicinal products
11 February 2016 EMA/255959/2016 Procedure Management and Committees Support Active substance: calcitonin salmon, synthetic analogue of eel calcitonin Procedure No.: PSUSA/00000494/201506 30 Churchill
More informationList of nationally authorised medicinal products
24 January 2018 EMA/270645/2015 Human Medicines Evaluation Division Active substance: azithromycin (systemic use formulations) Procedure no.: PSUSA/00010491/201704 30 Churchill Place Canary Wharf London
More informationList of nationally authorised medicinal products
09 June 2017 EMA/36849/2017 Human Medicines Evaluation Division Active substance(s): brimonidine / timolol Procedure No.: PSUSA/00000431/201609 30 Churchill Place Canary Wharf London E14 5EU United Kingdom
More informationList of nationally authorised medicinal products
10 September 2015 EMA/622830/2015 Procedure Management and Committees Support Active substance: azelastine Procedure no.: PSUSA/00000277/201412 30 Churchill Place Canary Wharf London E14 5EU United Kingdom
More informationList of nationally authorised medicinal products
7 July 2016 EMA/437334/2016 Procedure Management and Committees Support Division Active substance: Terazosin Procedure no.: PSUSA/00002895/201511 30 Churchill Place Canary Wharf London E14 5EU United Kingdom
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. Metformin HCl Mylan 500 mg/ 850 mg/ 1000 mg, film-coated tablets metformin hydrochloride
PACKAGE LEAFLET: INFORMATION FOR THE USER Metformin HCl Mylan 500 mg/ 850 mg/ 1000 mg, film-coated tablets metformin hydrochloride Read all of this leaflet carefully before you start taking this medicine.
More informationList of nationally authorised medicinal products
1 September 2017 EMA/580096/2017 Human Medicines Evaluation Division Active substance: terbutaline Procedure no.: PSUSA/00002897/201612 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationList of nationally authorised medicinal products
5 May 2017 EMA/288255/2017 Human Medicines Evaluation Division Active substance: pilocarpine (ophthalmic formulation) Procedure no.: PSUSA/00002410/201608 30 Churchill Place Canary Wharf London E14 5EU
More informationList of nationally authorised medicinal products
6 September 2018 EMA/619619/2018 Human Medicines Evaluation Division Active substance: haemophilus influenzae / klebsiella ozaenae / klebsiella pneumoniae / moraxella catarrhalis / staphylococcus aureus
More informationList of nationally authorised medicinal products
30 November 2017 EMA/817351/2017 Human Medicines Evaluation Division Active substance: Lidocaine / prilocaine (not centrally authorised product) Procedure no.: PSUSA/00001867/201703 30 Churchill Place
More informationList of nationally authorised medicinal products
14 April 2016 EMA/284169/2016 Procedure Management and Committees Support Active substance: influenza vaccine (split virion, inactivated) (non centrally products) Procedure no.: PSUSA/00010298/201508 30
More informationList of nationally authorised medicinal products
28 September 2017 EMA/639167/2017 Human Medicines Evaluation Division Active substance: zanamivir Procedure no.: PSUSA/00003141/201701 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. Metformin HCl Aurobindo 500 mg/ 850 mg/ 1000 mg, film-coated tablets metformin hydrochloride
PACKAGE LEAFLET: INFORMATION FOR THE USER Metfmin HCl Aurobindo 500 mg/ 850 mg/ 1000 mg, film-coated tablets metfmin hydrochlide Read all of this leaflet carefully befe you start taking this medicine.
More informationList of nationally authorised medicinal products
28 September 2017 EMA/658449/2017 Human Medicines Evaluation Division Active substance: olodaterol Procedure no.: PSUSA/00010245/201703 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationBIJSLUITER: INFORMATIE VOOR DE PATIËNT
BIJSLUITER: INFORMATIE VOOR DE PATIËNT Sitagliptine Teva 25 mg, filmomhulde tabletten Sitagliptine Teva 50 mg, filmomhulde tabletten Sitagliptine Teva 100 mg, filmomhulde tabletten Sitagliptin Read all
More informationList of nationally authorised medicinal products
12 July 2018 EMA/462856/2018 Human Medicines Evaluation Division Active substance: econazole, econazole nitrate / triamcinolone acetonide, econazole nitrate / zinc oxide Procedure no.: PSUSA/00001195/201711
More informationList of nationally authorised medicinal products
30 November 2017 EMA/795271/2017 Human Medicines Evaluation Division Active substance: vinorelbine Procedure no.: PSUSA/00003124/201704 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationBIJSLUITER: INFORMATIE VOOR DE PATIËNT
PACKAGE LEAFLET 1 BIJSLUITER: INFORMATIE VOOR DE PATIËNT Cinacalcet 30 mg Teva, filmomhulde tabletten Cinacalcet 60 mg Teva, filmomhulde tabletten Cinacalcet 90 mg Teva, filmomhulde tabletten Cinacalcet
More information(Invented) Name Strength Pharmaceutical Form. 3 mg/3 ml Solution for injection. Kytril 2 mg - Filmtabletten 2 mg Film-coated tablet Oral use
ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORMS, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTES OF ADMINISTRATION, MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES 1 Austria Austria Bulgaria Bulgaria
More informationList of nationally authorised medicinal products
13 September 2017 EMA/706786/2017 Human Medicines Evaluation Division Active substance: Octenidine dihydrochloride / phenoxyethanol Procedure no.: PSUSA/00002199/201701 30 Churchill Place Canary Wharf
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER
PACKAGE LEAFLET: INFORMATION FOR THE USER Simvastatin Aurobindo 5 mg film-coated tablets Simvastatin Aurobindo 10 mg film-coated tablets Simvastatin Aurobindo 20 mg film-coated tablets Simvastatin Aurobindo
More informationSimvastatin Teva 10 mg Film-coated Tablets Simvastatin Teva 20 mg Film-coated Tablets Simvastatin Teva 40 mg Film-coated Tablets Simvastatin
PACKAGE LEAFLET: INFORMATION FOR THE USER Simvastatin Teva 10 mg Film-coated Tablets Simvastatin Teva 20 mg Film-coated Tablets Simvastatin Teva 40 mg Film-coated Tablets Simvastatin Read all of this leaflet
More informationList of nationally authorised medicinal products
8 November 2017 EMA/845743/2017 Human Medicines Evaluation Division Active substance: ibuprofen, ibuprofen lysine (not indicated in ductus arteriosus) Procedure no.: PSUSA/00010345/201702 30 Churchill
More informationList of nationally authorised medicinal products
20 July 2016 EMA/270645/2015 Procedure Management and Committees Support Active substance: apomorphine Procedure no.: PSUSA/00000227/201511 30 Churchill Place Canary Wharf London E14 5EU United Kingdom
More informationPackage leaflet: Information for the patient. Optinate 30 mg film-coated tablets risedronate sodium
Package leaflet: Information for the patient Optinate 30 mg film-coated tablets risedronate sodium Read all of this leaflet carefully before you start taking this medicine because it contains important
More informationPackage leaflet: information for the user
Package leaflet: information for the user Rosuvastatin 5 mg film-coated tablets Rosuvastatin 10 mg film-coated tablets Rosuvastatin 20 mg film-coated tablets Rosuvastatin 40 mg film-coated tablets rosuvastatin
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. Etoricoxib
PACKAGE LEAFLET: INFORMATION FOR THE USER ARCOXIA 30 mg film-coated tablets ARCOXIA 60 mg film-coated tablets ARCOXIA 90 mg film-coated tablets ARCOXIA 120 mg film-coated tablets Etoricoxib Read all of
More informationPackage leaflet: Information for the user. Calciflex-D 3 Citron 500 mg/400 IU film-coated tablets calcium/cholecalciferol (vitamin D 3 )
Package leaflet: Information for the user Calciflex-D 3 Citron 500 mg/400 IU film-coated tablets calcium/cholecalciferol (vitamin D 3 ) For medicinal products available only on prescription: Read all of
More informationList of nationally authorised medicinal products
12 July 2018 EMA/497430/2018 Human Medicines Evaluation Division Active substance: tafluprost / timolol Procedure no.: PSUSA/00010324/201712 30 Churchill Place Canary Wharf London E14 5EU United Kingdom
More informationList of nationally authorised medicinal products
11 October 2017 EMA/691535/2017 Human Medicines Evaluation Division Active substance: Haemophilus type b conjugate vaccines Procedure no.: PSUSA/00001584/201702 30 Churchill Place Canary Wharf London E14
More informationOr You have other factors that increase your risk of having a heart attack, stroke or related health problems.
Package leaflet: information for the user Rosuvastatin 5 mg film-coated tablets Rosuvastatin 10 mg film-coated tablets Rosuvastatin 20 mg film-coated tablets Rosuvastatin 40 mg film-coated tablets rosuvastatin
More informationPlease note that this draft Annex I will be updated to amend information on concerned products/mahs
22 March 2018 EMA/197481/2018 Annex I List of the names, pharmaceutical forms, strengths of the medicinal products, routes of, applicants, marketing authorisation holders in the member states for for omega-3
More informationList of nationally authorised medicinal products
8 March 2018 EMA/182904/2018 Human Medicines Evaluation Division Active substance(s): fluticasone propionate / formoterol fumarate dihydrate Procedure No.: PSUSA/00010339/201707 30 Churchill Place Canary
More informationPackage leaflet: Information for the user. Kalcipos-D forte 500 mg/800 IU film-coated tablets. Calcium/cholecalciferol (Vitamin D3)
Package leaflet: Information for the user Kalcipos-D forte 500 mg/800 IU film-coated tablets Calcium/cholecalciferol (Vitamin D3) Read all of this leaflet carefully before you start using this medicine
More informationPackage leaflet: Information for the patient. Optinate Septimum 35 mg film-coated tablets risedronate sodium
Package leaflet: Information for the patient Optinate Septimum 35 mg film-coated tablets risedronate sodium Read all of this leaflet carefully before you start taking this medicine because it contains
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER Arcoxia 60 mg Film coated Tablets Arcoxia 90 mg Film coated Tablets etoricoxib
PACKAGE LEAFLET: INFORMATION FOR THE USER Arcoxia 60 mg Film coated Tablets Arcoxia 90 mg Film coated Tablets etoricoxib Read all of this leaflet carefully before you start taking this medicine. Keep this
More informationPackage leaflet: Information for the user. Valganciclovir 450 mg film-coated tablets valganciclovir
Package leaflet: Information for the user Valganciclovir 450 mg film-coated tablets valganciclovir Read all of this leaflet carefully before you start taking this medicine because it contains important
More informationPackage leaflet: Information for the user
Package leaflet: Information for the user Sevelamer Carbonate Rowex 800mg Film-coated tablets sevelamer carbonate Read all of this leaflet carefully before you start taking this medicine because it contains
More informationEuropean Medicines Agency decision
EMA/497687/2017 European Medicines Agency decision P/0245/2017 of 4 September 2017 on the refusal of a paediatric investigation plan and on the refusal of a deferral and on the granting of a waiver for
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. Valaciclovir Teva 500 mg Film-coated Tablets. Valaciclovir
PACKAGE LEAFLET: INFORMATION FOR THE USER Valaciclovir Teva 500 mg Film-coated Tablets Valaciclovir Read all of this leaflet carefully before you start taking this medicine. Keep this leaflet. You may
More informationCommission. Product. Notification. Decision. Issued 2 / affected 3 amended on 11/01/2019 PL
Procedural steps taken and scientific information after the authorisation Application Scope Opinion/ Commission Product Summary number Notification Decision Information 1 issued on Issued 2 / affected
More informationec naprosyn naprosyn for sale ec naprosyn 500mg dosage naprosyn prescription strength naprosyn 500mg indications naprosyn sr naprosyn rx naprosyn ec
Naprosyn Sr 500 naprosyn 500mg tablets naprosyn tablets 250 mg naprosyn tablets picture naprosyn generico naprosyn 375 mg oral tablet ec naprosyn 500mg what is naprosyn ec 500mg used for buy naprosyn online
More informationEuropean Medicines Agency decision
EMA/654883/2017 European Medicines Agency decision P/0312/2017 of 30 October 2017 on the acceptance of a modification of an agreed paediatric investigation plan for cabotegravir (EMEA- 001418-PIP01-13-M01)
More informationEuropean Medicines Agency decision
EMA/106209/2017 European Medicines Agency decision P/0074/2017 of 17 March 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for
More informationEuropean Medicines Agency decision
EMA/741983/2016 European Medicines Agency decision P/0324/2016 of 2 December 2016 on the acceptance of a modification of an agreed paediatric investigation plan for linagliptin (Trajenta), (EMEA-000498-PIP01-08-M06)
More informationPackage leaflet: Information for the patient. Levocetirizine Krka 5 mg film-coated tablets Levocetirizine dihydrochloride
Package leaflet: Information for the patient Levocetirizine Krka 5 mg film-coated tablets Levocetirizine dihydrochloride Read all of this leaflet carefully before you start taking this medicine because
More informationEuropean Medicines Agency decision
EMA/574564/2017 European Medicines Agency decision P/0278/2017 of 4 October 2017 on the acceptance of a modification of an agreed paediatric investigation plan for Japanese encephalitis vaccine (inactivated,
More informationEuropean Medicines Agency decision
EMA/75416/2018 European Medicines Agency decision P/0042/2018 of 16 February 2018 on the acceptance of a modification of an agreed paediatric investigation plan for dasatinib (Sprycel), (EMEA-000567-PIP01-09-M05)
More informationAnnex I. List of nationally authorised medicinal products and marketing authorisation applications
Annex I List of nationally authorised medicinal products and marketing authorisation applications 1 Annex IA: Medicinal products recommended for maintenance and marketing authorisation applications for
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER
PACKAGE LEAFLET: INFORMATION FOR THE USER 60 mg Film coated Tablets 90 mg Film coated Tablets 120 mg Film coated Tablets (etoricoxib) (etoricoxib) (etoricoxib) Read all of the leaflet carefully before
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. Metformin HCl Bluefish 500 mg/ 850 mg/ 1000 mg, film-coated tablets metformin hydrochloride
PACKAGE LEAFLET: INFORMATION FOR THE USER Metformin HCl Bluefish 500 mg/ 850 mg/ 1000 mg, film-coated tablets metformin hydrochloride Read all of this leaflet carefully before you start taking this medicine
More informationValtan 80mg Film-coated Tablets
Package leaflet: Information for the user Valtan 80mg Film-coated Tablets Valsartan Read all of this leaflet carefully before you start taking this medicine because it contains important information for
More informationEuropean Medicines Agency decision
EMA/434825/2017 European Medicines Agency decision P/0235/2017 of 9 August 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral for venetoclax (Venclyxto), (EMEA-002018-PIP02-16)
More informationPackage leaflet: Information for the patient
Package leaflet: Information for the patient Tevaquel 25 mg Film-coated Tablets Tevaquel 100 mg Film-coated Tablets Tevaquel 150 mg Film-coated Tablets Tevaquel 200 mg Film-coated Tablets Tevaquel 300
More informationEuropean Medicines Agency decision
EMA/848760/2017 European Medicines Agency decision P/0033/2018 of 30 January 2018 on the acceptance of a modification of an agreed paediatric investigation plan for sitagliptin (Januvia), (EMEA-000470-PIP01-08-M10)
More informationPackage leaflet: Information for the user. Clopidogrel 75 mg film-coated tablets. Clopidogrel
Package leaflet: Information for the user Clopidogrel 75 mg film-coated tablets Clopidogrel Read all of this leaflet carefully before you start taking this medicine because it contains important information
More informationPackage leaflet: Information for the user. Ibandroninezuur STADA 150 mg, filmomhulde tabletten. Ibandronic acid
Package leaflet: Information for the user Ibandroninezuur STADA 150 mg, filmomhulde tabletten Ibandronic acid Read all of this leaflet carefully before you start taking this medicine because it contains
More informationPackage leaflet: Information for the patient
Package leaflet: Information for the patient Atorvastatin 10 mg Film-coated Tablets Atorvastatin 20 mg Film-coated Tablets Atorvastatin 40 mg Film-coated Tablets Atorvastatin 80 mg Film-coated Tablets
More informationEuropean Medicines Agency decision
EMA/776083/2014 European Medicines Agency decision P/0001/2015 of 7 January 2015 on the acceptance of a modification of an agreed paediatric investigation plan for linagliptin (Trajenta) (EMEA-000498-PIP01-08-M04)
More informationInitial (Full) Marketing Authorisation application accelerated assessment timetables
30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact An agency of the European
More informationPackage leaflet: Information for the user. Montelukast 10 mg film-coated tablets. Montelukast
Package leaflet: Information for the user Montelukast 10 mg film-coated tablets Montelukast Read all of this leaflet carefully before you start taking this medicine because it contains important information
More informationEuropean Medicines Agency decision
EMA/398442/2016 European Medicines Agency decision P/0191/2016 of 15 July 2016 on the acceptance of a modification of an agreed paediatric investigation plan for agomelatine (Valdoxan, Thymanax), (EMEA-001181-PIP01-11-M03)
More informationPackage leaflet: information for the user. Valaciclovir Bluefish 500 mg Film-Coated Tablets Valaciclovir
Package leaflet: information for the user Valaciclovir Bluefish 500 mg Film-Coated Tablets Valaciclovir Read all of this leaflet carefully before you start taking this medicine because it contains important
More informationUpdate on public hearing
Update on public hearing PCWP/HCPWP joint meeting Presented by Juan Garcia Burgos on 0 September 017 Head of Public Engagement Department An agency of the European Union A public hearing provides An opportunity
More informationEuropean Medicines Agency decision
EMA/155875/2015 European Medicines Agency decision P/0062/2015 of 1 April 2015 on the acceptance of a modification of an agreed paediatric investigation plan for sitagliptin (Januvia), (EMEA-000470-PIP01-08-M09)
More informationEuropean Medicines Agency decision
EMA/761887/2015 European Medicines Agency decision P/0307/2015 of 21 December 2015 on the acceptance of a modification of an agreed paediatric investigation plan for odanacatib (EMEA- 001123-PIP01-11-M03)
More informationPackage Leaflet: Information for the user. Tadalafil 10 mg film-coated tablets Tadalafil
Package Leaflet: Information for the user Tadalafil 10 mg film-coated tablets Tadalafil Read all of this leaflet carefully before you start taking this medicine because it contains important information
More informationEuropean Union herbal monograph on Eschscholzia californica Cham., herba
28 January 2015 EMA/HMPC/680372/2013 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Eschscholzia californica Cham., herba Final Discussion in Working Party on European
More informationEuropean Medicines Agency decision
EMA/788583/2016 European Medicines Agency decision P/0363/2016 of 21 December 2016 on the agreement of a paediatric investigation plan and on the granting of a waiver for dipalmitoylphosphatidylcholine
More informationEU PSUR Work Sharing Summary Assessment Report AFLAMIN (aceclofenac) HU/H/PSUR/0030/002 HU
P-RMS EU PSUR Work Sharing Summary Assessment Report AFLAMIN (aceclofenac) HU/H/PSUR/0030/002 HU Invented name of the medicinal product(s) INN (or common name) of the active substance(s) MAHs whose PSURs
More informationEuropean Union herbal monograph on Ruscus aculeatus L. rhizoma
30 January 2018 EMA/188804/2017 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Ruscus aculeatus L. rhizoma Draft Initial assessment Discussion in Working Party on European
More informationPrasugrel hydrochloride film-coated tablets 5 mg and 10 mg product-specific bioequivalence guidance
31 May 2018 EMA/CHMP/158772/2016/Rev.1 Committee for Medicinal Products for Human Use (CHMP) Prasugrel hydrochloride film-coated tablets 5 mg and 10 mg Draft Agreed by Pharmacokinetics Working Party April
More information